Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
15 juin 2023 16h44 HE
|
Vera Therapeutics
BRISBANE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
08 juin 2023 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
07 juin 2023 08h00 HE
|
Vera Therapeutics
Pivotal Phase 3 Trial for Atacicept in IgA Nephropathy Initiated Today Late-breaking results of ORIGIN Phase 2b trial supporting further evaluation of atacicept 150 mg as a potential...
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
11 mai 2023 07h30 HE
|
Vera Therapeutics
36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN selected for presentation as a late breaking clinical trial at ERA Congress 2023 Plan to initiate a pivotal Phase 3 clinical...
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
04 mai 2023 08h00 HE
|
Vera Therapeutics
BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
28 mars 2023 07h30 HE
|
Vera Therapeutics
Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline in the 150mg dose group at 24...
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
27 févr. 2023 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
06 févr. 2023 16h05 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
01 févr. 2023 21h52 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc., (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative...
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
01 févr. 2023 16h01 HE
|
Vera Therapeutics
BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for...